

Special Issue

Molecular Mechanisms of Genitourinary Cancers

Message from the Guest Editor

Genitourinary tumors, including prostate, urothelial, renal, and testis tumors, occur in a large number of cancer patients worldwide. Over the decades, several treatments have enriched the therapeutic scenario of genitourinary cancers. Among these, there are immune checkpoint inhibitors, new-generation tyrosine-kinase inhibitors, antibody–drug conjugates, anti-FGFR drugs, and anti-androgen receptor inhibitors. Unfortunately, none of these treatments are curative and most patients tend to develop mechanisms of progression; for these reasons, understanding the molecular mechanisms of genitourinary cancers is crucial for the best management of these patients. This Special Issue aims to evaluate the molecular mechanisms of genitourinary cancers, highlighting the novel treatments of such cancers and the future directions in this field of research. It seeks to explore the mechanisms of action of the therapies that have been developed and investigate the pathways of resistance. In this Special Issue, we welcome reviews, mini-reviews, new methods, and original research articles that will advance our understanding of the molecular mechanisms of genitourinary cancers.

Guest Editor

Dr. Giandomenico Roviello
Department Health Sciences Florence, University of Florence, 50139
Florence, Italy

Deadline for manuscript submissions

closed (20 June 2025)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/224977

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))